Jobs

🚨🚨UPDATED EVERY WEEK  🚨🚨

29 th of January:
1) Italian Ministry of Education, University and Research - The isolation and chemical-physical and biological characterisation of human anti-CNA antistaphylococcal antibodies for use in biomedicine

2)  Postdoctoral Research Associate - University of York, United Kingdom

3) Postdoctoral Research Fellow - Harvard University, United States

4) Research Associate, Microbiology/Molecular Biology [LKCMedicine] - Nanyang Technological University, Singapore

5) Postdoctoral Research Associate - University of Sydney, Australia

6) Centro de Engenharia Biológica da Universidade do Minho - PhD Research Fellowship - CENTRE OF BIOLOGICAL ENGINEERING: CEB-BI-14-2025 - New microfluidic tools for rapid phage therapy testing and manufacturing

7) Helmholtz-Zentrum für Infektionsforschung GmbH - Helmholtz Junior Research Group Leaders (f/m/d) (with tenure option)

8) PhD fellowship in the discovery of small antimicrobial phage proteins- Frederiksberg, Danmark (Denmark)

23 th of January:
1) Visiting Research Specialist - Carl R. Woese Institute for Genomic Biology - University of Illinois at Urbana Champaign, United States

16 th of January:
1) Postdoctoral researcher Bioinformatics of microbiome-virus-host interactions in insects - Radboud University Medical Center - Netherlands

2) Research Associate / Postdoctoral Fellow - Honeybee Bacteriophages and Advanced Biotechnology
University of Canterbury, New Zealand

3) Lund University - Bioinformatician in phage–bacteria Interactions

9 th of January:
1) Senior Scientist - The Medicines And Healthcare Products Regulatory Agency - London

2) Research Associate, Microbiology/Molecular Biology [LKCMedicine] - Nanyang Technological University, Singapore


Comments

Post a Comment

Popular posts from this blog

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more